[CNP_P9] Poster Session 9

Fri. Oct 11, 2019 1:40 PM - 3:10 PM Poster Hall (Multi-purpose Hall)

座長：嶽北　佳輝（関西医科大学精神神経科学教室）

10月11日（金）　13:40～15:10　ポスター会場（福岡国際会議場 2階多目的ホール）
10月12日（土）　16:40～17:25　ポスター会場（福岡国際会議場 2階多目的ホール）

+Add all to schedule

1:40 PM - 1:48 PM

[CNP-P9-1] Risk/Benefit balance of antipsychotic monotherapy and adjunctive therapy in the treatment of adult patients with major depressive disorder: A systematic review and meta-analysis

^○Katsuhiko HAGI¹, Tadashi NOSAKA¹, Andrei PIKALOV² (1. Sumitomo Dainippon Pharma Co., Ltd., 2. Sunovion Pharmaceuticals, Inc.)

1:48 PM - 1:56 PM

[CNP-P9-2] Efficacy and safety of lurasidone and other second-generation antipsychotics for bipolar depression in children: A systematic review and network meta-analysis

^○Katsuhiko HAGI¹, Melissa P DELBELLO², Daisy Ng MAK³, Aditi KADAKIA³, Vincent HELLER⁴, Rajpal SINGH⁵, Tadashi NOSAKA¹, Antony LOEBEL³ (1. Sumitomo Dainippon Pharma Co., Ltd., 2. University of Cincinnati, College of Medicine, 3. Sunovion Pharmaceuticals, Inc., 4. Real-World Insights, IQVIA, 5. HEOR Scientific Services, IQVIA)

1:56 PM - 2:04 PM

[CNP-P9-3] Safety of lurasidone for the treatment of adult patients with schizophrenia: Relationship between timing of administration and risk of adverse events

^○Katsuhiko HAGI¹, Tadashi NOSAKA¹, Andrei PIKALOV² (1. Sumitomo Dainippon Pharma Co., Ltd., 2. Sunovion Pharmaceuticals, Inc.)

2:04 PM - 2:12 PM

[CNP-P9-4] Inter-individual variability of antipsychotic-related prolactin level

^○Shinpei NONEN¹, Yoshiteru TAKEKITA², Toshihiko KINOSHITA², Kato MASAKI² (1. School of Pharmacy, Hyogo University of Health Sciences, Hyogo, Japan, 2. Department of Neuropsychiatry, Kansai Medical University)